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SUMMARY
As core components of the microRNA-induced
silencing complex (miRISC), Argonaute (AGO) pro-
teins interact with TNRC6 proteins, recruiting other
effectors of translational repression/mRNA destabili-
zation. Here, we show that LIMD1 coordinates the
assembly of an AGO-TNRC6 containing miRISC
complex by binding both proteins simultaneously at
distinct interfaces. Phosphorylation of AGO2 at Ser
387 by Akt3 induces LIMD1 binding, which in turn en-
ablesAGO2 to interactwith TNRC6Aanddownstream
effector DDX6. Conservation of this serine in AGO1
and4 indicates thismechanismmaybea fundamental
requirement for AGO function and miRISC assembly.
Upon CRISPR-Cas9-mediated knockout of LIMD1,
AGO2 miRNA-silencing function is lost and miRNA
silencing becomes dependent on a complex formed
by AGO3 and the LIMD1 family member WTIP. The
switch to AGO3 utilization occurs due to the presence
of a glutamic acid residue (E390) on the interaction
interface, which allows AGO3 to bind to LIMD1,
AJUBA, and WTIP irrespective of Akt signaling.
INTRODUCTION
MicroRNAs are 22 nucleotide non-coding RNA molecules that
silence gene expression post-transcriptionally (Bartel, 2004).
Their loading onto Argonaute (AGO) proteins facilitates base-
pairing to mRNA targets with partial complementarity and ulti-
mately translational repression and mRNA degradation (Hunt-
zinger and Izaurralde, 2011; Hutvagner and Simard, 2008).
Repression is executed by the microRNA-induced silencing
complex (miRISC), a large multi-subunit complex assembled
by AGO-mediated recruitment of GW182/TNRC6 proteins and
downstream effector complexes (Behm-Ansmant et al., 2006;
Chekulaeva et al., 2011; Lian et al., 2009; Liu et al., 2005).
TNRC6 proteins facilitate translational repression, mRNA desta-
bilization, and ultimately degradation of target mRNAs via
recruitment of effector proteins to the miRISC, such as those
involved in decapping (DCP1/2), RNA unwinding (DDX6), and
deadenylation (CCR4-NOT) (Bazzini et al., 2012; Chen et al.,
2014; Chu and Rana, 2006; Rouya et al., 2014).
Despite significant advances in our understanding of the ter-
minal effects ofmiRNAs on their targets, the early steps ofmiRISC
assembly and its functional activation remain poorly understood.
Recent studies have explored the role of post-translational modi-
fication of AGOproteins (Jee and Lai, 2014;R€udel et al., 2011). For
example, phosphorylation of AGO2 Y529 inhibits loading of small
RNAs (R€udel et al., 2011), while EGFR-dependent phosphoryla-
tion of AGO2 Y393 prevents processing of looped precursor
RNAs into mature miRNAs (Shen et al., 2013). Additionally, Akt3-
mediated phosphorylation of AGO2 S387 reduces the mRNA
cleavage activity of AGO2 and drives it toward translational
repression associated with miRNA-mediated silencing (Horman
et al., 2013; Zeng et al., 2008). It has also recently been shown
that primary T cells display a signaling-dependent shift in
miRISC configuration. While the majority of miRNAs were found
in low-molecular-weight miRISC complexes in resting T cells,
stimulation of phosphatidylinositol 3-kinase (PI3K) signaling
caused an increased association of miRNAs with high-mole-
cular-weight miRISC complexes and an enhancement of
miRNA-mediated silencing (La Rocca et al., 2015). These data
indicate that miRISC assembly into an active complex and the
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protein-protein interactions therein are highly dynamic processes,
controlled by signal transduction cascades.
To date, the four human AGO proteins (AGO1–4) have been
demonstrated to function largely redundantly with regards to
miRNA loading and target recognition, with the functionally
dominant AGO currently attributed to the expression levels of
these proteins (Dueck et al., 2012; Su et al., 2009; Wang et al.,
2012). How these overlapping functions are facilitated in light
of recent findings demonstrating the role of signaling pathways
in the regulation of miRNA biogenesis and function is unclear.
Interestingly, plasticity in AGO usage following genetic ablation
has been observed (Wang et al., 2012), although the mechanism
underpinning this switch remains unknown.
The discovery that AGO2 activity is regulated by phosphoryla-
tion, and indeed other post-translational modifications, raises
the question as to whether all four human AGO proteins are sub-
ject to regulation by signaling, and whether, through differential
signal transduction and phosphorylation, may not exhibit com-
plete redundancy (Golden et al., 2017; Lopez-Orozco et al.,
2015; Patranabis and Bhattacharyya, 2016; Sahin et al., 2014;
Shen et al., 2013; Zeng et al., 2008). Horman and colleagues
suggest that the AGO2 S387 phosphorylation diverts its activity
from mRNA cleavage to (or toward) miRNA-mediated silencing
(Horman et al., 2013). However, this study did not consider the
high homology within the S387-containing L2 domain between
AGO2 and other human AGO proteins, which are not involved
in small interfering RNA (siRNA) silencing. We therefore sought
to determine whether signaling regulates miRISC assembly
and function across the entire AGO family and whether this regu-
lation would identify an additional dimension of AGO family
member functional specificity.
LIMD1 is a component ofmiRISC required for silencing (James
et al., 2010). However, its precise function in miRISC and miRNA
silencing is poorly understood. Here, we demonstrate that
LIMD1 is crucial for AGO2 miRNA function and that loss of
AGO2-LIMD1-mediated miRNA silencing reveals a previously
unknown mechanism of AGO selection, with LIMD1 association
being a key determinant of AGO utilization. LIMD1 is required for
the recruitment of TNRC6A and downstream effectors (DDX6) to
AGO2. We show that Akt3-mediated phosphorylation of AGO2
(S387) promotes a phospho-dependent interaction with LIMD1
that is vital for enabling engagement of AGO2 with TNRC6A,
revealing the mechanism by which AGO-S387 phosphorylation
regulates miRISC function. The phosphorylation-dependent
interaction with LIMD1 also extends to the other human
AGO family members, with a conserved serine also present in
AGO1 and AGO4. AGO3 lacks this conserved serine residue
but instead contains a phospho-mimic glutamic acid residue
(E390), which facilitates signaling-independent binding to
LIMD1 family members. Our findings demonstrate that loss of
LIMD1 abolishes AGO2-mediated miRNA silencing and results
in redistribution of AGO utilization for miRNA silencing to AGO3.
RESULTS
AGO Utilization Is Determined by LIMD1
Members of the LIMD1 family (LIMD1, AJUBA, andWTIP) of LIM-
domain-containing proteins associate with miRISC and are
required for miRNA-mediated silencing (James et al., 2010). To
examine the role of LIMD1 on AGO2 function, we designed a
Renilla luciferase reporter containing five targeted or non-tar-
geted miR-99/100 binding sites in its 30 UTR. We observed sig-
nificant de-repression of the targeted reporter upon AGO2,
TNRC6A, or LIMD1 siRNA-mediated knockdown in HeLa cells,
whereas little or no de-repression was seen with depletion of
AGO1, 3, or 4 (Figure 1A and S1A). The high specificity of this
reporter for AGO2 is surprising as a previous study did not find
evidence for miRNA sorting into AGO1, 2, or 3 in HeLa cells
and concluded that association of a particular miRNA with a
particular AGO solely reflected AGO protein abundance (Dueck
et al., 2012). Moreover, mRNA levels of the targeted reporter
were unchanged, indicating that, at the time points analyzed,
the reporter is subject to miRNA-mediated translation inhibition
rather than target cleavage (Figure S1B).
To investigate the mechanistic function of LIMD1 in miRNA
silencing independently of engagement of the RNAi machinery,
we genetically ablated LIMD1 in HeLa cells using CRISPR-Cas9
technology (FigureS1C).Unexpectedly,we found that repression
of the miR-99/100 reporter was equivalent in LIMD1+/+ and
LIMD1/ cell lines (50% repression of the targeted reporter),
although expression of exogenous LIMD1 enhanced silencing
in the LIMD1/ line (Figure S1D). To explore the mechanism un-
derlying the maintenance of silencing in the LIMD1/ line, we
analyzed reporter activity when this isogenic HeLa CRISPR pair
was treated with siRNAs targeting AGO1–4 (Figures 1B and
1C). We observed a switch in the requirement for AGO proteins
in this pair of HeLa lines. AGO2 depletion only led to de-repres-
sion of miRNA silencing in the LIMD1+/+ line, whereas, in the
LIMD1/ line, AGO3 depletion produced a de-repression. As
AGO2 comprises the majority (60%) of the AGO pool in HeLa
cells (Petri et al., 2011) and its levels remained unchanged upon
LIMD1 loss (Figure S1C), the switch in AGOutilizationmay reflect
the importance of LIMD1 specifically for AGO2 function in HeLa.
In order to interrogate the generality of this switch in AGO uti-
lization, we employed a let-7a-targeted reporter. Similarly, we
observed that loss of LIMD1 (LIMD1/) rendered AGO2 unable
to contribute to silencing, whereas in LIMD1+/+ cells, de-repres-
sion was induced upon AGO2 knockdown (Figures S1E and
S1F). In contrast to the miR-99/100 reporter, however, AGO1
and AGO3 knockdown resulted in de-repression of the let-7a-
targeted reporter, regardless of LIMD1 genotype, indicating
this reporter and miRNA demonstrated a broader specificity for
AGO and LIMD1 family proteins. To rule out the possibility that
the observed switch in AGO usewas due to the use of a synthetic
30 UTR miRNA reporter, we also examined whether LIMD1 loss
resulted in a switch in AGO requirement of two natural 30 UTRs
reporters—FGFR3 and MTOR, which each contain, in addition
to other miRNA sites, single miR-99/100 sites (Figures 1H, 1I,
S1G, and S1H). Both reporters showed a switch from AGO1/2
dependency, to AGO1/3 and AGO4, respectively, in the absence
of LIMD1.
LIMD1 Is Critical for the Interaction of AGO2 with
TNRC6A and DDX6
We next examined the binding partners and function of LIMD1 in
miRISC in more detail to shed light on why loss of LIMD1
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appeared to render AGO2 unable to contribute to silencing of
both synthetic and natural 30 UTRs and how the switch in
AGO utilization was facilitated. Immunofluorescence (IF) staining
of endogenous LIMD1, AGO2, and TNRC6A showed triple coloc-
alization to processing bodies (P-bodies) (Figure 2A). To investi-
gate direct endogenous association of AGO2 and TNRC6A with
LIMD1 in situ, we performed proximity ligation assays (PLA)
(So¨derberg et al., 2006) for AGO2:LIMD1 and TNRC6A:LIMD1
(Figures 2B and S2A). We observed PLA signal for LIMD1 with
both AGO2 and TNRC6A. In agreement with recent reports
(Chen et al., 2014; Mathys et al., 2014), our PLA analysis demon-
strated TNRC6A directly associated with CNOT9 (CNOT9 con-
tains W-binding pockets to accommodate tryptophan residues
from TNRC6A). By contrast CNOT1 did not exhibit PLA signal
with TNRC6A; these data may be reflective of the lack of direct
binding evidence between these proteins and the absence of a
structurally resolved binding interface (Chen et al., 2014; Mathys
et al., 2014). This supports the validity and specificity of the
endogenous LIMD1 direct interactions with AGO2/TNRC6A.
LIM-domain-containing proteins are characterized by their
ability to act as scaffolds in multi-protein complexes (Koch
et al., 2012). We therefore reasoned that the close proximity
and association observed between LIMD1, AGO2, and TNRC6A
could indicate a scaffolding role for LIMD1within themiRISC.We
examined the endogenous colocalization of AGO2 with TNRC6A
andmiRISC component DDX6 by IF in HeLa cells upon treatment
with siRNA targeting LIMD1 (Figures S2B–S2D). LSM1 is re-
quired for the assembly of P-bodies but does not affect
miRNA-silencing function; we therefore included siRNA target-
ing LSM1 as a control for P-body disruption. LIMD1 depletion
did not disrupt the colocalization of AGO2 with TNRC6A or
DDX6. By contrast, and as described in the literature, LSM1
knockdown caused a decrease in visible AGO2/TNRC6A/
DDX6 P-bodies (Chu and Rana, 2006).
To rule out a possible false-negative effect due to the limited
resolution of confocal microscopy (240 nm) (Nature Photon,
2009), we repeated our analysis using PLA, which detects pro-
teins within 40 nm of each other (Figures 2C–2F). PLA analysis
demonstrated that interaction of AGO2 with TNRC6A and
DDX6 was significantly reduced upon LIMD1 knockdown,
whereas LSM1 knockdown did not reduce this interaction, and
in fact increased interaction of AGO2 with TNRC6A. In agree-
ment with these data, reporter assays performed in cells treated
with the same siRNAs demonstrated significant de-repression of
a miR-99/100 reporter upon loss of LIMD1 but not LSM1 (Fig-
ure S2E). These findings confirm that assembly of P-bodies is
a consequence rather than a cause of miRNA silencing (Eulalio
et al., 2007) and demonstrate that the de-repressive effect of
LIMD1 depletion on miRNA silencing is not dependent on
the disassembly of P-bodies. Together, our data show that
LIMD1 contributes to maintaining the interactions of AGO2
with TNRC6A and DDX6.
Figure 1. Genetic Ablation of LIMD1 Switches Dependency upon Argonaute Species for miRNA Silencing
(A) psiCHECK-2-miR-99/100 luciferase reporter (NT, non-targeting reporter; T, targeting reporter; mean ± SEM; n = 4 treated with indicated siRNAs (SCR, non-
targeting control).
(B and C) (B) psiCHECK-2-miR99/100 reporter in CRISPR-Cas9 gene-edited HeLa cells with Cas9 alone control (LIMD1+/+) or (C) LIMD1 knockout (LIMD1/)
cells, treated with the indicated siRNAs.
(D and E) (D) psiCHECK-2-FGFR3 (endogenousmutant [MUT] or wild-type [WT] 30 UTR) reporter in CRISPR-Cas9 gene-edited HeLa cells with Cas9 alone control
(LIMD1+/+) or (E) LIMD1 knockout (LIMD1/) cells, treated with the indicated siRNAs.
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In order to further pursue the discrepancy between protein
localization to P-bodies and the interaction between miRISC
proteins, we performed endogenous IF for AGO1, 2, 3, and 4
with both TNRC6A and DDX6 in the isogenic LIMD1/ HeLa
CRISPR pair (Figures S3A and S3B). Loss of LIMD1 had no
visible effect on AGO1, 2, or 3 colocalization with TNRC6A or
Figure 2. LIMD1 Interacts with miRISC Components AGO2 and TNRC6A and Promotes Their Association
(A) Endogenous IF of the indicated proteins in HeLa cells.
(B) Endogenous in situ interaction determined by proximity ligation assay (PLA) of the indicated proteins. PLA signal orange, cells stained with DAPI (top); PLA
signal white for visual clarity (bottom). Scale bars, 10 mm.
(C) PLA analysis of endogenous AGO2 and TNRC6A interaction in HeLa cells treated with SCR (non-targeting), LIMD1, or LSM1 siRNA. PLA signal orange, cells
stained with DAPI (top); PLA signal white for visual clarity (bottom).
(D) Quantification of PLA interaction events in (C), displayed as a stacked histogram. Data are mean ± SEM, n = 3, **p < 0.001, ***p < 0.0001, determined using the
chi-square test.
(E) PLA analysis of endogenous AGO2 and DDX6 interaction, as in (C).
(F) Quantification of (E) as in (D).
(G) Endogenous co-immunoprecipitation of LIMD1 with the indicated proteins from HeLa cells (*IgG heavy chain).
(H) Endogenous coIP of indicated miRISC components with AGO2 from CRISPR-Cas9 gene-edited HeLa LIMD1+/+ or LIMD1/ cells.
(I) Endogenous coIP of indicated miRISC components with DDX6 from CRISPR-Cas9 gene-edited HeLa LIMD1+/+ or LIMD1/ cells expressing Xpress (Xpr)
vector only (VO) or LIMD1.
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DDX6 in P-bodies (AGO4 did not colocalize with TNRC6A/DDX6
in either cell line). Furthermore, we did not detect any change in
colocalization of EYFP-tagged AGO2with endogenous TNRC6A
upon inhibition of Akt3 by siRNA, treatment with Akt inhibitor
MK-2206, or overexpression of AGO2 S387A point mutant (Fig-
ure S4A). We therefore performed complementary PLA and
endogenous immunoprecipitation experiments and observed
strikingly that LIMD1 knockout caused significant impairment
of endogenous AGO2 interaction with TNRC6A and DDX6 (Fig-
ures S4B–S4G), in agreement with functional reporter assays
performed in these lines (Figure 1). Furthermore, re-expression
of Xpress (Xpr)-tagged LIMD1 in the LIMD1/ line restored the
interaction of DDX6 with AGO2 and TNRC6A (Figure 2I), poten-
tially explaining the enhancement of silencing observed when
LIMD1 is overexpressed in a LIMD1-null background (Fig-
ure S1D). These data therefore demonstrate that endogenous
interaction assays, including PLA and IP, are more accurate
methods of determining endogenous miRISC protein-protein
interaction, as opposed to visible colocalization within P-bodies.
In summary, loss of LIMD1 profoundly impaired the ability of
AGO2 to interact with TNRC6A and downstream effectors within
miRISC required for miRNA-mediated silencing.
LIMD1 Interacts with AGO2 and TNRC6A via Specific
Domains
Having demonstrated that LIMD1 is required to scaffold the
interaction of AGO2 and TNRC6A, we next sought to map the
interaction interfaces on all three proteins. LIMD1 contains three
tandemly arrayed LIM domains (protein-protein interacting zinc
fingers) in its C-terminal region and a preceding proline/serine-
rich unstructured domain referred to as the pre-LIM (residues
1–471). Our previous work demonstrated that AGO2 bound to
the pre-LIM portion of LIMD1 (James et al., 2010). To identify
the precise AGO Binding (AB) motif in the pre-LIM, we co-immu-
noprecipitated Xpr-tagged full-length LIMD1 or a series of
LIMD1 internal deletion mutants with EYFP-tagged AGO2. We
found that deletion of amino acids 140–166 within LIMD1 abro-
gated the interaction with AGO2 (Figure 3A). The identification
of amino acids 140–166 as the ABmotif in LIMD1 was confirmed
by direct binding assays using purified un-tagged AGO2
(hAGO2) (De and Macrae, 2011) (Figure 3B) and maltose binding
protein (MBP)-tagged full-length LIMD1 or AB motif (Figure 3C).
Generation of a set of HeLa lines lentivirally transduced to ex-
press sh-SCR (non-targeting) or sh-LIMD1 RNA and RNAi-resis-
tant wild-type (WT) LIMD1 (rr-LIMD1) or LIMD1 deletion mutants
(Figure S5A) demonstrated loss of silencing of the miR-99/100
reporter in sh-LIMD1 and rr-D140–166 lines (Figure 3D). In
contrast, we observed that cells expressing the larger adjacent
rr-D186–260 LIMD1 deletion mutant (which retains AGO2 bind-
ing, Figure 3A) displayed equivalent levels of silencing to that
seen in rr-LIMD1 cells, thus providing an additional control for
the impact of internal deletions on the secondary structure of
the pre-LIM domain. These data indicate that, as predicted,
the ability of LIMD1 to bind AGO2 via its AB motif is critical for
its miRNA-silencing function.
We next performed complementary direct binding assays
to identify the corresponding LIMD1-binding domain within
AGO2, using a series of GST-AGO2N- and C-terminal truncation
mutants (Figures S5B and S5C). We determined that the Linker 2
(L2) domain of AGO2, which lies between the PAZ and MID do-
mains, was necessary for direct interaction with the AB motif of
LIMD1 (MBP-LIMD1 140–166) and full-length LIMD1 (Figure 3E).
We note that the additional bands present in these purified AGO2
mutants are either degradation products (as determined by
western blot and mass spectrometry (Figures S5D–S5G) or bac-
terial Hsp70 (DnaK), which did not affect binding to LIMD1
(Figure S5H).
As our PLA experiments also indicated a close association of
LIMD1 with TNRC6A, we sought to confirm whether this
occurred independently of AGO2. We found that deletion of
the LIMdomains (C-terminal) of LIMD1 resulted in loss of interac-
tion with EGFP-tagged TNRC6A in co-immunoprecipitation ex-
periments (Figure 3F). Deletion of the LIMD1 AB motif did not
affect interaction with TNRC6A, demonstrating that the interac-
tion of LIMD1 with TNRC6A is not dependent upon LIMD1 inter-
action with AGO2. Next, we determined that the N-terminal
AGO-binding domain (ABD) of TNRC6A (Eulalio et al., 2009b)
was responsible for binding to LIMD1; coIP experiments in
HEK293T cells using EGFP-tagged TNRC6A truncations and
Xpr-LIMD1 revealed that deletion of TNRC6A amino acids
1–883 resulted in complete loss of binding to LIMD1 (Figure 3G).
In summary, the pre-LIM region of LIMD1 is responsible for
interaction with AGO L2 (via the AB, aa 140–166), and the C-ter-
minal LIM domains interact with the N-terminal portion of
TNRC6A. Therefore, we provide evidence that LIMD1 functions
as a central scaffold protein and a core component of miRISC,
forming an integral link between AGO2 and TNRC6A through
simultaneous direct contacts with each (Figure 3H).
Akt3-Mediated Phosphorylation of S387 in the AGO2 L2
Domain Is Necessary for Interaction with LIMD1
It has been proposed that Akt3-dependent phosphorylation of
AGO2 S387 promotes its miRNA function and opposes its target
cleavage activity (Horman et al., 2013). AGO2 S387 phosphory-
lation was suggested to increase the association of AGO2 with
TNRC6A via an unknown mechanism. As S387 is located within
the L2 region of AGO2, we tested whether phosphorylation of
this residue could trigger the association between AGO2 and
LIMD1 and subsequent recruitment of TNRC6A to AGO2. We
generated constructs expressing phospho mutant (AGO2
S387A) or phospho-mimic (AGO2 S387E) versions of EYFP-
AGO2 and compared their ability to interact with LIMD1 in immu-
noprecipitation assays. AGO2 S387A had reduced binding to
LIMD1, whereas the phospho-mimic version of AGO2 (AGO2
S387E) rescued interaction with LIMD1 (Figures 4A and S6B).
The interaction profile of LIMD1 with these AGO2 constructs
was mirrored by endogenous TNRC6A and DDX6, which
displayed significantly reduced binding to AGO2 S387A, and
rescue of binding with AGO2 S387E (Figures S6A and S6B).
The importance of S387 phosphorylation for LIMD1 binding
was further confirmed by direct binding assays between the
AB motif of LIMD1 and GST-AGO2 WT or GST-AGO2 S387E,
which revealed enhanced binding of the AGO2 phospho mimic
to LIMD1 AB motif (Figure 4B). The dependency on S387
for LIMD1 association was also evident in the degree of colo-
calization of AGO2 and LIMD1 in U2OS cells transfected with
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mTan-LIMD1 and the EYFP-AGO2 constructs (Figures 4C, 4D,
and S6C). Compared to WT AGO2, AGO2 S387A and S387E
showed a 9.4-fold decrease and 2.1-fold increase in colocaliza-
tion with LIMD1, respectively. These data indicate that the inter-
action of AGO2 with LIMD1 is dependent on the phosphorylation
status of AGO2 S387.
Next, we tested whether the interaction between LIMD1 and
AGO2 could be directly promoted by overexpression of Akt3,
thought to be the primary kinase responsible for phosphorylation
of AGO2 S387 (Horman et al., 2013). We immunoprecipitated
endogenous LIMD1 from serum-starved HeLa cells transfected
with an empty vector or a constitutively active myristoylated
Akt3 (HA-myr-Akt3) (Song et al., 2008) and found that Akt3 signif-
icantly enhanced both the levels of phospho-S387 AGO2 (using
a phospho-S387-specific antibody (Zeng et al., 2008; Fig-
ure S6D) and the interaction of AGO2 with LIMD1 (Figure 4E).
Figure 3. LIMD1 Bridges AGO2 and TNRC6A via Distinct Interaction Sites
(A–C) (A) Co-immunoprecipitation (coIP) of Xpress (Xpr)-LIMD1 and internal deletion mutants with GFP-AGO2 from HEK293T lysate. (B) Purified un-tagged
crystallography grade hAGO2 used in (C) direct binding assay with MBP-VO, MBP-LIMD1, or MBP-LIMD1 140 166 (AB motif) (highlighted by arrows).
(D) psiCHECK-2-miR99/100 luciferase reporter (NT [non-targeting], T [targeting]) assay performed in shRNA knockdown and rescue (RNAi resistant [rr]) LIMD1
HeLa cells (mean ± SEM; n = 3).
(E) Schematic of GST-AGO2 truncation mutants and summary of binding to LIMD1 AB motif.
(F) CoIP of Xpr-LIMD1 and deletion mutants with GFP-TNRC6A from HEK293T lysate.
(G) CoIP of TNRC6A and truncation mutants with Xpr-LIMD1 from HEK293T lysate.
(H) Graphical representation of domain interaction of AGO2, LIMD1, and TNRC6A. The AB motif of LIMD1 (aa 140–166) directly binds linker 2 (L2) of AGO2, and
the LIM domains of LIMD1 bind the N-terminal AGO-binding domain (ABD) of TNRC6A (SD, silencing domain).
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In a complementary assay, treatment of the HeLa CRISPR-Cas9
isogenic pair with the Akt inhibitor MK-2206 demonstrated that
interaction of AGO2, LIMD1, and TNRC6A with DDX6 was signif-
icantly impaired in LIMD1+/+ cells upon Akt inhibition (Figure 4F);
under these conditions, the interaction of the complex was
equivalent to that of the LIMD1/ line (Figure S6E). Treatment
of the LIMD1/ cells with MK-2206 entirely abolished the
complex interactions, indicating that there is some residual inter-
action of AGO2 with miRISC in the absence of LIMD1, which is
also Akt dependent. In agreement with these assays, siRNA-
mediated knockdown of Akt3 in U2OS cells resulted in a 9-fold
reduction in colocalization between EYFP-AGO2 and mTan-
LIMD1 (Figures 4G, 4H, and S6F). In summary, these data
confirm that Akt3-mediated phosphorylation of AGO2 S387 is
required for AGO2-LIMD1 interaction.
Activated Phospho-S387-AGO2 Requires LIMD1
for Formation of a Functional AGO2-miRISC
To determine whether phosphorylated AGO2 (S387) is depen-
dent on LIMD1 for miRISC formation and function, we exam-
ined the activity of the miR-99/100 reporter in HeLa CRISPR
lines treated with siRNA against AGO2, where WT AGO2 or
S387 phospho-site mutants were re-expressed (Figures 5A,
5B, and S6G). In LIMD1+/+ cells, AGO2 knockdown caused
the expected de-repression. Re-expression of AGO2 WT and
S387E rescued silencing, whereas AGO2 S387A was unable
to rescue silencing, in agreement with published data (Horman
et al., 2013). In contrast, in the LIMD1/ line, AGO2 knock-
down did not cause any de-repression, and re-expression of
any AGO2 construct (WT or S387 mutant) similarly had no
effect.
We next determined whether the previously established regu-
lation of AGO2 miRNA silencing by Akt3 was in fact mediated by
LIMD1 (Horman et al., 2013). Upon siRNA-mediated depletion of
Akt3, we observed de-repression of the miR-99/100 reporter in
LIMD1+/+ cells, but this had no effect in the LIMD1/ line, where
silencing was maintained (Figures 5C and S6H). Taken together,
these data demonstrate that the activating effect of Akt3-medi-
ated phosphorylation on AGO2 is dependent on subsequent
interaction with LIMD1. In the absence of LIMD1, miRNA
silencing still occurs independently of Akt3. To investigate how
LIMD1 loss caused this striking inhibition of phospho-AGO2 ac-
tivity, we examined the interaction of phospho-AGO2 with
TNRC6A and DDX6 upon loss of LIMD1. PLA analysis with the
phospho-AGO2 (S387)-specific antibody demonstrated that
loss of LIMD1 significantly disrupts the ability of phospho-
AGO2 to bind both TNRC6A and DDX6 endogenously (Figures
5D–5G, S6I, and S6J). These data therefore demonstrate that
AGO2 phosphorylation by Akt3 has no activating effect on
miRNA silencing in the absence of LIMD1 due to the fact that
the loss of this scaffold protein dissociates phospho-AGO2
from TNRC6A/miRISC and precludes AGO2-dependent miRNA
silencing. These data are in agreement with the functional obser-
vations made upon LIMD1 loss (Figure 1), where we observed
functional replacement by AGO3. We therefore went on to
examine whether this mechanism of phospho-dependent
recruitment of LIMD1 family proteins was conserved across all
human AGO proteins.
AGO1 and AGO4 Exhibit Phosphorylation-Dependent
Interaction with LIMD1 Family Proteins
A significant structural homology exists between the four
human AGO proteins; our alignment analysis revealed that
AGO2 S387 is conserved in the L2 domains of AGO1 and
AGO4 (Figure 6A). We therefore investigated whether there
was a conserved phospho-dependent mechanism of AGO1,
2, and 4 interaction with LIMD1 family members. First, we found
that LIMD1, Ajuba, and WTIP interacted with all four AGOs (Fig-
ures S7A, S7B, and data not shown). LIMD1 also directly bound
to the L2 domain of AGO1 (Figure S7C), and, in a similar manner
to AGO2, mutation of the conserved serine in AGO1 (S385) to
alanine inhibited colocalization with LIMD1, whereas mutation
to glutamic acid rescued this colocalization (Figures S7D and
S7F). Furthermore, knockdown of Akt3 by siRNA significantly
reduced AGO1:LIMD1 colocalization, suggesting that Akt3
may also phosphorylate AGO1 S385 (Figures S7E and S7G).
Point mutation of the conserved serine (S377) in AGO4 pro-
duced the same disruption and rescue of colocalization with
LIMD1 as observed with AGO1 and 2 (Figures S7H and S7J).
Taken together these data suggest a common mechanism
may exist whereby human AGO 1, 2 and 4 are activated for
miRNA-silencing function by phosphorylation of a conserved
serine residue, which directs their interaction with LIMD1
and family members and subsequent recruitment to TNRC6A/
miRISC. Given the ability of LIMD1 to colocalize with three
AGO proteins in a phospho-dependent manner, we also
demonstrated that the LIMD1 family member Ajuba, also
colocalized with AGO1 and that this was dependent on the
phosphorylation status of S385 (Figure S7I). These data support
a fundamentally conserved mechanism of phosphorylation-
dependent activation of AGO proteins by recruitment and regu-
lation of all three members of this LIM-domain-containing
family, LIMD1, Ajuba, and WTIP.
AGO3 Interacts with LIMD1 Family Proteins
Independently of Akt3 Phosphorylation
In contrast to AGO1 and AGO4, AGO3 possesses a phosphory-
lation-mimicking glutamic acid residue at amino acid position
390 (Figure 6A). Given that we found AGO3 can rescue loss of
AGO2 miRNA function in the absence of LIMD1, we postulated
that this phospho-mimic residue may facilitate interaction with
LIMD1 and/or its closely related family members Ajuba/WTIP
independently of Akt3 signaling. This could be a mechanism ex-
plaining the switch to AGO3 utilization upon deletion of LIMD1
(Figure 1).
To interrogate this hypothesis, we first determined that AGO3
colocalizes with LIMD1, consistent with IP data (Figure S7A), and
that this is significantly reduced upon mutation of the phospho-
mimic residue to alanine (E390A) (Figures 6B and 6C). Similarly,
colocalization of AGO3 with Ajuba was reduced by mutation of
E390 to alanine (Figures S7K and S7L). In striking contrast to
AGO2, siRNA-mediated knockdown of Akt3 did not affect
AGO3/LIMD1 colocalization (Figures 6D and 6E). WTIP interac-
tion with AGO3 was also unaffected by Akt inhibition (MK-
2206), as opposed to AGO2,which demonstrated loss of interac-
tion (Figures 6F and 6G), and siRNA-mediated knockdown of
Akt3 similar had no effect on AGO3 colocalization with WTIP
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Figure 4. Binding of LIMD1 to AGO2 Is Dependent on Akt3-Mediated S387 Phosphorylation
(A) Co-immunoprecipitation (IP) of Xpr-LIMD1 with EYFP-AGO2 WT, AGO2S387A (phospho-deficient), and AGO2S387E (phospho-mimic) point mutants from
HEK293T lysate.
(B) Purified recombinant GST-AGO2 L2 or L2 S387E were used in direct binding assay with MBP-LIMD1 full-length or AB motif (140–166).
(legend continued on next page)
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(Figures 6H and 6I). These data therefore demonstrate that
AGO3 interaction with LIMD1 family proteins occurs indepen-
dently of Akt signaling as a result of the naturally occurring phos-
pho-mimic residue E390.
We observed activation of AGO3miRNA function when LIMD1
protein expression was entirely ablated (Figure 1), and phos-
phorylated AGO2 was unable to engage with TNRC6A and
silencing effectors (Figure 5). In the LIMD1/ HeLa cell line,
siRNA depletion of WTIP yielded a significant de-repression of
the miR-99/100 reporter, whereas Ajuba knockdown did not
(data not shown). Therefore, to determine whether WTIP was
responsible for engaging AGO3 in the absence of LIMD1, we
performed siRNA knockdown of AGO3 or WTIP, singularly or in
combination, in the LIMD1/ HeLa cell line. We discovered
that WTIP is required for silencing of a miR-99/100 reporter in
these cells (Figure 7A). Furthermore, depletion of WTIP and
AGO3 in combination led to an almost complete de-repression
of silencing (Figure 7A). Concurrent with this, we discovered an
increase in the number of AGO3 P-bodies in the LIMD1/ line
compared to LIMD1+/+ (Figures S7M and S7N), indicating that
while a reduction in an AGO miRNA-silencing function is not
necessarily associated with dissociation from P-bodies (as is
the case with AGO2), an increase in AGO3 silencing function
may be associated with an increase in its recruitment to
P-bodies. Furthermore, we observed an increase in AGO3:WTIP
interaction in the LIMD1/ line compared to LIMD1+/+ (Figures
7B and 7C).
AGO function in miRNA silencing is critically dependent
on association with TNRC6 proteins, which enable recruitment
of several effector complexes that mediate target mRNA
decapping and deadenylation. We therefore examined
whether TNRC6A recruitment to AGO2 and AGO3 was altered
in the presence and absence of LIMD1, which would explain
the apparent switch in AGO function. Endogenous immuno-
precipitation of AGO2 or AGO3 from the HeLa LIMD1/
CRISPR cell line pair demonstrated that, in contrast to the
loss of TNRC6A interaction with AGO2, AGO3 interaction
with TNRC6A was significantly enhanced upon loss of
LIMD1 (Figures 7D and 7E).
These interaction data elucidate the mechanism by which loss
of LIMD1 causes a switch in cellular AGO dependency (Figure 1).
We have discovered that, in HeLa cells, loss of LIMD1 causes
dependency upon AGO2 to switch to AGO3, and this is associ-
ated with enhanced (phosphorylation-independent) interaction
of AGO3 with LIMD1 family member WTIP, and with TNRC6A
as the effector of silencing. These data therefore define the
mechanism by which AGO2-S387 phosphorylation is an
activating event for silencing. Additionally, as all LIMD1 family
proteins interact with AGO1–4 in a phospho-dependent manner,
these data suggest a general mechanism whereby specific AGO
proteins are activated for miRNA function by their phosphoryla-
tion and subsequent recruitment of LIMD1 family proteins, thus
enabling miRISC formation.
DISCUSSION
LIMD1 Acts as a Molecular Clamp to Secure Phospho-
AGO2 and TNRC6A Together within miRISC
Wedetermined that LIMD1 binds directly to AGO2 and TNRC6A
at distinct interfaces: the AGO-binding motif (AB motif) of
LIMD1 binds the L2 domain of AGO2, and the C-terminal LIM
domains of LIMD1 bind the amino-terminal ABD of TNRC6A,
independently of AGO binding (Figure 3) (Eulalio et al., 2009a;
Pfaff et al., 2013; Takimoto et al., 2009). It is important to note
that our data do not suggest the AGO-TNRC6A association
can only occur via LIMD1; the MID/PIWI (P-element induced
wimpy testis) domains of AGO2 that directly bind TNRC6A tryp-
tophan residues do not bind to LIMD1 (Figure 3E) (Schirle and
MacRae, 2012). Additionally, the association of the C-terminal
silencing domain of TNRC6A with PABP/CNOT9/CNOT1/
DDX6 does not preclude the binding of LIMD1, which interacts
with the N-terminal half of TNRC6A (Figure 3D) (Eulalio et al.,
2009a). Therefore, our data indicate that LIMD1 acts as a mo-
lecular ‘‘clamp’’ by binding to both AGO and TNRC6A proteins
simultaneously to secure their association and commit both
proteins and associated effectors to the miRNA-silencing
pathway: AGO2 association with TNRC6A/miRISC and its
miRNA-silencing activity is significantly impaired upon LIMD1
loss (Figures 1A–1C and 2).
It has been demonstrated that activation of miRNA silencing is
dependent on Akt3-mediated phosphorylation of AGO2 at S387
(Horman et al., 2013). We have determined that this phosphory-
lation promotes association of AGO2 with LIMD1 and subse-
quent recruitment of TNRC6A and downstream silencing
effector complexes (Figures 4 and 5). Our findings therefore
reveal the functional consequence of S387 phosphorylation,
which underpins an apparent preference of AGO utilization
directed by LIMD1 family member proteins. In agreement with
our findings, La Rocca et al. recently identified phosphoryla-
tion-dependent activation of miRNA silencing by PI3K, a kinase
that lies upstream of Akt3 (La Rocca et al., 2015). Although this
study did not examine the precise changes in AGO2 phosphor-
ylation, it discovered an increase in the molecular mass of
AGO2 upon pathway activation, most likely via the recruitment
of other effector proteins, which would include TNRC6A,
DDX6, and, from our data, LIMD1.
(C) Co-localization of EYFP-AGO2/S387 point mutants with mTan-LIMD1 in U2OS cells. Nucleus outline in white.
(D) Quantification of percentage of AGO2/S387 P-bodies colocalized with LIMD1 in (C).
(E) Immunoprecipitation of endogenous LIMD1 from HeLa cells transfected with HA-VO or HA-myristolated Akt3, and western blot analysis of the indicated
proteins; pAGO2 is S387.
(F) Immunoprecipitation of DDX6 from HeLa LIMD1+/+ or LIMD1/ treated with DMSO or Akt inhibitor MK-2206 and analyzed for the indicated proteins by
western blot; pAKT is S473.
(G) Co-expression of EYFP-AGO2 (WT) with mTan-LIMD1 in U2OS cells treated with non-targeting (SCR) or AKT3 siRNA. Nuclear outlines in white.
(H) Quantification of number of AGO2 P-bodies colocalized with LIMD1 in (G).
Data shown are mean ± SEM, n = 3, *p < 0.05, **p < 0.001. Scale bars, 10 mm.
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AGO Interaction with LIMD1 Family Proteins Occurs via
a Common Phosphorylation-Dependent Mechanism
The AGO L2 domain is a 98-residue, extended L-shaped coil that
connects the PAZ and MID domains of AGO proteins (Elkayam
et al., 2012; Schirle andMacRae, 2012). The AGO3 S387 residue
phosphorylated by Akt3 is conserved in human AGO1 and 4 (Fig-
ure 6A). Our data demonstrate that LIMD1 can interact with all
four AGO proteins (Figure S8A) and that association with
AGO1 and 4 is also dependent on the ability of this conserved
serine residue to be phosphorylated (Figures S8D–S8I). Taken
together with previous studies demonstrating that AGO1 is
phosphorylated (R€udel et al., 2011), these data support a hy-
pothesis of a common AGO-activating mechanism by Akt3
and/or other unidentified kinases. AGO3 does not contain this
Figure 5. LIMD1 Is Required for Phospho-S387-AGO2 to Engage TNRC6A/DDX6 for miRNA-Mediated Silencing
(A and B) (A) psiCHECK-2-miR99/100 reporter assay in HeLa CRISPR-Cas9 LIMD1+/+ or (B) LIMD1/ cell lines transfected with non-targeting (SCR) or AGO2
siRNA and EYFP-AGO2, EYFP-AGO2S387A, or EYFP-AGO2S387E.
(C) miR99/100 reporter assay in in above HeLa CRISPR-Cas9 cell lines transfected with non-targeting (SCR) or AKT3 siRNA.
(D) PLA analysis of endogenous phospho-AGO2 (S387):TNRC6A interaction in situ in HeLa CRISPR-Cas9 LIMD1+/+ or LIMD1/ lines. PLA signal orange, cells
stained with DAPI (top); PLA signal white for visual clarity (bottom). Scale bars, 10 mm.
(E) Quantification of PLA interaction events in (D), displayed as stacked histograms. Data are mean ± SEM, n = 3, total of 200 cells determined using the chi-
square test.
(F) PLA analysis of phospho-AGO2 (S387):DDX6 interaction in above HeLa CRISPR-Cas9 cell lines.
(G) Quantification of (F) as in (E).
Unless otherwise stated, data are mean ± SEM, n = 3, *p < 0.05, **p < 0.001, ***p < 0.0001 according to the Student’s t test.
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Figure 6. AGO3 E390 Acts as a Phospho-mimic, Facilitating Interaction with LAW Independently of Akt Signaling
(A) AGO2 S387 is highly conserved within AGO1 (S385) and AGO4 (S377). AGO3 does not contain an equivalent serine residue but instead an adjacent phospho-
mimic glutamic acid residue (E390).
(B) Colocalization of EYFP-AGO3/E390 point mutants with mTan-LIMD1 in U2OS cells.
(C) Quantification of percentage of AGO3 P-bodies colocalized with LIMD1 in (B).
(D) Colocalization of EYFP-AGO3 with LIMD1 in U2OS cells treated with non-targeting (SCR) or AKT3 siRNA.
(E) Quantification of percentage of AGO3 P-bodies colocalized with LIMD1 in (D), n = 2.
(F) Immunoprecipitation (IP) of EYFP-VO, -AGO2, or -AGO3 from HEK293T lysate co-transfected with Xpress (Xpr)-WTIP and treated with DMSO or Akt inhibitor
MK-2206.
(G) Quantification of WTIP interaction with AGO2 and 3, in (F). Data are mean densitometry relative to AGO2 (DMSO), ±SEM, n = 3.
(H) Colocalization of EYFP-AGO3 with WTIP in U2OS cells treated with non-targeting (SCR) or AKT3 siRNA.
(I) Quantification of percentage of AGO3 P-bodies colocalized with WTIP in (H), n = 2.
Unless otherwise stated, quantification data are mean ± SEM, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001, n.s., not significant.
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conserved serine residue but rather contains a phospho-mimic
glutamic acid residue, which directs interaction with LIMD1
family members independently of Akt signaling (Figure 7).
Horman et al. postulated that phosphorylation of S387 repre-
sented a molecular switch between the siRNA and miRNA func-
tion of AGO2 (Horman et al., 2013). However, our data indicate
the Akt3-mediated phosphorylation of AGO1, 2 (and possibly
AGO4) could also be considered as a switch from OFF to ON
for miRNA-silencing function. Furthermore, if one were to
consider the possibility of a cell state with no Akt3 signaling,
where silencing may only be possible through AGO3 function,
then an activation of Akt3 could activate a switch from the default
AGO3 silencing to any or all of the AGO1-, 2-, or 4-dependent
mechanisms. Our work also opens up the possibility for func-
tional differences between the four human AGO proteins that
have been previously been described to act redundantly in the
miRNA pathway (Dueck et al., 2012; Su et al., 2009). Future
work will address this possibility.
Although many components and processes of the miRNA
pathway are highly conserved between humans and Drosophila,
an important difference is that, in Drosophila, only one of two
AGO proteins, AGO1, functions in the miRNA pathway (Fo¨rste-
mann et al., 2007; Tomari et al., 2007). Within the L2 domain of
Drosophila AGO1, S387 is not conserved. This may suggest
that the evolution of S387 in human AGO2 (and equivalent ser-
ines in AGO1 and 4) was necessary for coordinating the re-
sponses of multiple AGOs to signaling inputs. It remains to be
determined whether a protein in Drosophila fulfills the role of
LIMD1 with regard to promoting interaction between AGO1
and GW182. Recent data from Golden et al. have shown that
cyclic phosphorylation at highly conserved serine residues in
the PIWI domain of human AGO2 (S824–S834) promotes effi-
cient miRNA silencing (Golden et al., 2017). They noted that
these residues are conserved in human AGOs 1–4 and
Drosophila AGO1 but not in Drosophila AGO2, which only func-
tions in the siRNA pathway. Thus, the evolution of several regu-
latory phospho sites, including S387, may be integral to the
expansion of the AGO gene family between fly and human, all
of which can function in miRNA-mediated silencing.
LIMD1 Directs AGO Family Member Utilization for
miRNA Silencing
While siRNA and shRNA-mediated knockdown of proteins is
able to provide functional insights, the complete genetic abla-
tion of a protein can reveal longer-term adaptations in cells
and alternative pathways to maintain homeostasis. Through
the use of CRISPR-Cas9 technology, we ablated LIMD1
expression and observed a switch in AGO dependency for
silencing from AGO2 to AGO3. In the LIMD1/ cell line, we
found that phospho-AGO2 S387 and total AGO2 interaction
Figure 7. AGO2 miRNA Function Switches to AGO3 with LIM Family Member WTIP in the Absence of LIMD1
(A) LIMD1/ HeLa cells transfected with non-targeting (SCR) and the indicated siRNAs (**p<0.01 according to student’s T-test).
(B) PLA of AGO3 and WTIP in HeLa CRISPR-Cas9 cell lines.
(C) Quantification of PLA interaction events in (B), displayed as a stacked histogram.
(D) IP of endogenous AGO2 or AGO3 from HeLa CRISPR-Cas9 cells, coIP of endogenous TNRC6A.
(E) Quantification of TNRC6A coIP with AGO2 and 3 in HeLa CRISPR-Cas9 cells in (D). Data are mean densitometry relative to LIMD1+/+ AGO2/3.
Unless otherwise stated, all data are ±SEM, n = 3, *p < 0.05, **p < 0.001, ***p < 0.0001, n.s., not significant, according to the Student’s t test.
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with TNRC6A and DDX6 was significantly impaired, and AGO2
miRNA function was entirely ablated irrespective of its phos-
phorylation status (Figure 5). In parallel assays, LSM1, which
is required for P-body assembly but not miRNA silencing
(Chu and Rana, 2006; Eulalio et al., 2007, 2009a), affected
neither AGO2 association with TNRC6A/DDX6 nor AGO2-
dependent miRNA silencing (Figures 2C–2F). These data
indicate that the effects observed upon LIMD1 loss occur
specifically as a result of its scaffold role in the AGO2:TNRC6A
association and not as a general effect of loss of P-body struc-
tural integrity. Indeed, re-expression of LIMD1 in the LIMD1/
line not only enhanced silencing, but also rescued the interac-
tion of AGO2 with TNRC6A and DDX6 (Figure 2J).
The contributions of each AGO protein to miRNA-mediated
silencing has been attributed to their expression levels, with
AGO2 being the most abundant and therefore of greatest impor-
tance (Wang et al., 2012). However, our data reveal that LIMD1
family proteins are important determinants of AGO utilization
and show that AGO levels per se may not necessarily determine
functional importance. The typically low AGO3 expression in
various tissues and cell types has been ascribed to the high pro-
portion of rarely used codons in its mRNA (Valdmanis et al.,
2012). Despite this, we have shown AGO3 does function in
miRNA silencing and specifically functions in the absence of
the Akt3-AGO2-LIMD1 signaling axis. Determination of AGO
utilization and the cooperation of different AGOsmay, in addition
to specific pairing with LIMD1 family proteins, be context depen-
dent with respect to miRNA site geometry in the 30 UTR and
the distribution of a particular miRNA among AGO proteins
expressed in the cell. These considerations warrant further
investigation to more clearly define the regulation of miRNA-
dependent silencing.
We may speculate that, for our miR-99/100 reporter, in the
presence of LIMD1, the majority of targeted sites on the re-
porter mRNA are occupied by AGO2-LIMD1 with a minor
contribution of AGO3-WTIP. Potential interactions between
LIMD1 and WTIP may be required for overall stability of the
multiple RISCs assembled on this 30 UTR, and short-term
loss of either one (in the context of siRNA knockdown) would
lead to significant de-repression of silencing. With LIMD1
loss, AGO3-WTIP may increase in occupancy of remaining/
free sites on the reporter thereby rendering silencing highly
dependent on AGO3.
Loss of LIMD1 by genetic ablation did not affect silencing of
the let-7a reporter, but the underlying AGO utilization was
altered, with AGO2 no longer contributing to silencing (Figures
S1E and S1F). In this respect, as seen with the miR-99/100 re-
porter, long-term loss of LIMD1 led to functional adaptation to
maintain miRNA silencing and also revealed the particular
involvement of LIMD1 in AGO2-dependent miRNA silencing.
The let-7a reporter contained six tandem let-7a sites, and its
repression was dependent on AGO1, 2, and 3. This result
suggests that, for this particular synthetic 30 UTR, a broad coop-
erative alliance of AGO1–3 and LIMdomain proteins is necessary
for silencing and that short-term loss of any component by siRNA
knockdown is highly unfavorable.
Post-transcriptional gene silencing involving miRNAs was first
discovered over 20 years ago but only now are its precise mech-
anism and place within the array of cellular signaling networks
becoming more clearly defined. There is now intense interest
in how post-translational modification of components of miRNA
biogenesis and miRISC can regulate and fine-tune both siRNA
and miRNA-mediated gene silencing. A particularly active topic
in the field is how phosphorylation of miRISC proteins can affect
miRNA loading and recruitment to miRISC, ultimately affecting
functionality (Golden et al., 2017; Horman et al., 2013; Lopez-
Orozco et al., 2015; McKenzie et al., 2016; R€udel et al., 2011;
Shen et al., 2013; Warner et al., 2016; Yang et al., 2014; Zeng
et al., 2008). Our findings identify that phosphorylation causes
AGO selection for silencing by recruitment of a LIMD1 family
member and sequential assembly of AGO-TNRC6A miRISC.
EXPERIMENTAL PROCEDURES
Cell Culture
HEK293T, HeLa, and U2OS cells were routinely cultured in DMEM (Sigma)
supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, and
100 mg/mL streptomycin. Akt inhibitor MK-2206 was used at a final concentra-
tion of 10 mM in complete DMEM, for 16 hr.
Plasmids
The generation of constructs used in this study are detailed in the Supple-
mental Experimental Procedures.
Luciferase Reporter Assays
Firefly and Renilla luciferase activities were assayed with the Dual-Luciferase
Reporter Assay System (Promega) according to the manufacturer’s
instructions. Further details are provided in the Supplemental Experimental
Procedures.
Immunoprecipitation and Western Blotting
Routine methods to immunoprecipitate proteins were employed and detailed
in the Supplemental Experimental Procedures. Antibodies used in the study
are detailed in Table S2.
Expression of Recombinant Proteins and Purification
Details are provided in Supplemental Experimental Procedures.
MBP Direct Binding Assay
Details are provided in Supplemental Experimental Procedures.
GST-Pull-Down Assays
Details are provided in Supplemental Experimental Procedures.
Real-Time qPCR
Details are provided in Supplemental Experimental Procedures.
Lentiviral Line Generation
To obtain pseudotyped lentivirus (recombinant HIV-1 with vesicular stomatitis
virus G [VSV-G] envelope protein), we used the gene delivery and production
system developed by Naldini et al. (1996). Details for selection are in the
Supplemental Experimental Procedures.
Protein Mass Spectrometry
Details are provided in Supplemental Experimental Procedures.
IF Microscopy
For analysis of miRISC protein localization, cells were fixed with 4% parafor-
maldehyde and stained according to standard procedures, which are detailed
in the Supplemental Experimental Procedures.
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PLA
PLAs were performed on HeLa cells prepared as for IF assays, including pri-
mary antibody incubation. Subsequently, Duolink In Situ PLA probes (1:10 in
2% BSA/0.025% Tween PBS) and orange detection reagents were used in
accordance with the manufacturer’s instructions. For negative controls,
each of the primary antibodies was addedwith an immunoglobulin G (IgG) anti-
body for the corresponding antibody species (rabbit, mouse, or goat, as
appropriate). PLA signal in images has been digitally intensified for visual
clarity in printed figures.
CRISPR-Cas9 Cell Line Generation
LIMD1 knockout CRISPR cell lines (HeLa) were generated using the lenti-
CRISPR v2 plasmid (Sanjana et al., 2014), acquired from Addgene (plasmid
52961). Further details for guide RNA sequence and clonal selection are in
the Supplemental Experimental Procedures.
Quantification and Statistical Analysis
PLA interaction events were counted using the ImageJ ‘‘Analyze Particles’’
function. Data were stratified according to quartiles for the control condition
and displayed as a stacked histogram. Statistical significance was calculated
using chi-square analysis (for grouped data).
Quantification of western blots was performed by densitometric analysis
using ImageJ software. For quantification of relative binding in co-immunopre-
cipitation assays, co-immunoprecipitated proteins were double normalized
first against their input levels and second against levels of immunoprecipitated
protein species. Binding data displayed are relative to WT or untreated
conditions.
Statistical significance was calculated using the Student’s t test, unless
otherwise specified. Significance is represented as *p < 0.05, **p < 0.001, or
***p < 0.0001 throughout.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2017.06.027.
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